Biocon receives EIR for its Biologics Drug Product facility in Bengaluru

Biocon has received an Establishment Inspection Report (EIR) from the USFDA for its Biologics Drug Product facility in Bengaluru, stating the inspection is closed.

Biocon had undergone a surveillance (routine) cGMP inspection of this Drug Product facility in Bengaluru from 22 August to 30 August 2019. The receipt of EIR indicates a successful closure of this inspection.

Powered by Capital Market - Live News